Unraveling biomarkers in Parkinson’s disease: the role of Insulin-like growth factor-1 (IGF-1) and DAT imaging by Picillo, Marina
ANNO ACCADEMICO 2016/2017 




DIPARTIMENTO DI MEDICINA E CHIRURGIA 
 
DOTTORATO DI RICERCA IN MEDICINA TRASLAZIONALE E 
DELL’INVECCHIAMENTO ATTIVO 
Curriculum: Marcatori molecolari, radiologici, clinici e cognitivo-
comportamentali dello sviluppo e del declino funzionale 
 Ciclo: XXIX
Coordinatore: Prof. Corrado Rubino 
 
TESI DI DOTTORATO IN: 
 
Unraveling biomarkers in Parkinson’s disease: the role of Insulin-like 





   RELATORE 
Chiar.ma Prof.  










Table of contents 
List of abbreviations                                                                                                                      2 
Part I – Introduction                                                                                                                      4  
Parte II - Scope of the thesis                                                                                                          10 
Part III - Exploring the association between serum IGF-1 and cognitive functions                      
in early, drug-naïve Parkinson’s disease                                                                
Part IV - Investigating the association between dopaminergic dysfunction and 
anxiety in de novo Parkinson's disease 
Part V - Unraveling the relationship between cognition and dopaminergic 
dysfunction in de novo Parkinson's disease: a longitudinal prospective study 
Appendix 











List of abbreviations 
BJLOT: Benton Judgment of Line Orientation test 
DAT: dopamine transporter 
GDS-15: 15-item Geriatric Depression Scale 
HC: healthy controls 
HVLT-DLRY: Hopkins Verbal Learning Test Delayed Recall 
HVLT-DR: Hopkins Verbal Learning Test discrimination recognition 
HVLT-IR: Hopkins Verbal Learning Test immediate recall 
HVLT-R: Hopkins Verbal Learning Test – Revised 
IGF-1: insulin-like growth factor-1 
JOLO: Benton Judgment of Line Orientation 
LNS: Letter Number Sequencing 
MCI: mild cognitive impairment 
MDS-UPDRS: Movement Disorder Society-Unified Parkinson’s Disease Rating Scale 
MDS-UPDRS-III: Movement Disorders Society version of the Unified Parkinson’s disease rating 
scale part III 
MoCA: Montreal Cognitive Assessment 
PD: Parkinson’ s disease 
PPMI: Parkinson's Progression Markers initiative 
SBRs: striatal binding ratios 
SD: standard deviation 
! 3!
SDMT: Symbol Digit Modalities test 
SF: Semantic fluency 
SPECT: single positron emission computerized tomography 



















Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's 
disease, affecting up to 10 million individuals worldwide [1]. Although symptomatic treatment 
ameliorates motor symptoms, currently there are no disease-modifying treatments.  
A biomarker is defined by the National Institutes of Health as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention” [2]. Thus, biomarkers include clinical 
data, measurements of biological samples (e.g., plasma, serum, cerebrospinal fluid) and application 
of  brain imaging techniques to detect changes in brain structure and function.  
As for PD, biomarkers represent tools potentially suitable for either clinical or research settings and 
useful in predicting onset, confirming diagnosis, detecting progression and evaluating the response 
to disease-modifying treatments. In addition, biomarkers’ trends in different stages of disease may 
reflect the widespread neurochemical and neuroanatomical changes that occur throughout the 
course of PD and, thus, possibly suggest new insights in the pathophysiological mechanisms 
underlying disease progression [3,4] (Figure 1). The range of available biomarkers in PD is fast 
expanding and includes an increasing number of laboratory, clinical and imaging data [5]. Indeed, 
the latter two represent the cornerstones of the diagnostic criteria for PD recently proposed by the 
International Parkinson and Movement Disorders Society (MDS) task force on the definition of PD 
[5-7]. As for imaging biomarkers, the largest amount of evidence is available for SPECT DAT Scan 
which is currently used in both clinical and research settings [8,9]. On the contrary, scant of data are 
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available for laboratory biomarkers. As such, although serum biomarkers would represent a 
fascinating, cost-effective and easy to collect source of information in PD, no valid and reliable 
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Figure 1. Clinical and imaging biomarkers tackling pathological changes in Parkinson’s 
disease from prodromal to middle/advanced phase. 
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Scope of the thesis 
The scope of this thesis is to explore the relationship between specific laboratory and imaging 
biomarkers and cognitive as well as behavioral features in de novo, drug-naïve PD patients.  
In Part III of the thesis, we explored the role of serum Insulin-Growth Factor 1 (IGF-1) at diagnosis 
as a marker of worse cognitive performances. 
In Part IV and V, we focused on the SPECT DAT Scan and aimed at demonstrating a direct 
relationship between nigro-striatal denervation and specific cognitive and behavioral features.  
Indeed, we already reached such results in our small, single-center de novo PD population [1-4]. 
Thus, the main goal of the studies proposed in the present thesis were to replicate our previous 
findings in the largest cohort of de novo, drug-naïve PD patients existing worldwide, the 
Parkinson’s Progression Markers Initiative (PPMI) study promoted by the Michael J Fox 
Foundation for Parkinson’s research and following prospectically 424 de novo PD patients and 196 
Healthy Controls (http://www.ppmi-info.org). Indeed, we took advantage of being an active part of 
the PPMI study and obtained the approval from the Steering Committee for dosing the IGF-1 serum 
levels of all the PPMI participants. The remaining data used for this thesis have been downloaded 
from the PPMI website (http://www.ppmi-info.org/access-data-specimens/download-data). The 
whole statistical design as well the execution for the three studies proposed have been performed 
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Exploring the association between serum IGF-1 and cognitive functions in 
early, drug-naïve Parkinson’s disease 
Published in Plos One 2017;12(10):e0186508. 
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Abstract 
Objective: Cognitive deficits are common in Parkinson’s disease (PD) since the early stages and 
many patients eventually develop dementia. Yet, occurrence of dementia in PD is unpredictable. 
Evidence supports the hypothesis that insulin-like growth factor-1 (IGF-1) is involved in cognitive 
deficits. Our aim was to evaluate the relationship between serum IGF-1 levels and 
neuropsychological scores in a large cohort of drug-naïve PD patients during the earliest stages of 
the disease. 
Methods:  Serum IGF-1 levels were determined in 405 early, drug-naïve PD patients and 191 
healthy controls (HC) enrolled in the Parkinson’s Progression Markers Initiative (PPMI). The 
association between serum IGF-1 levels and neuropsychological scores was evaluated with linear 
regression analysis. 
Results: IGF-1 levels were similar in PD and HC. In PD patients the lowest IGF-1 quartile was a 
predictor of lower performances at the Semantic Fluency task (β=-3.46, 95%CI: -5.87 to -1.01, 
p=0.005), the Symbol Digit Modalities Score (β=-2.09, 95%CI: -4.02 to -0.15, p=0.034), and 
Hopkins Verbal Learning Test Retention (β=-0.05, 95%CI: -0.09 to -0.009, p=0.019).  
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Conclusions: Lower serum IGF-1 levels are associated to poor performances in cognitive tasks 
assessing executive function, attention and verbal memory in a large cohort of early PD patients. 
Follow-up studies are warranted to assess if IGF-1 is related to the development of dementia in PD. 
Introduction 
Cognitive disturbances are common findings in Parkinson’s disease (PD) since the earliest stages, 
manifesting with executive as well as with visuospatial deficits [1]. Cognitive function typically 
decline over time, with many patients eventually developing dementia [2]. Evolution to dementia is 
a key milestone in PD progression as denotes a subgroup of patients with worse prognosis and 
represents a heavy burden for both patients and caregivers. Among all, age, male gender and 
presence of subtle cognitive impairment have been identified as the most consistent predictors of 
dementia [2]. Despite considerable efforts of the research community, valid biomarkers of cognitive 
impairment for PD have yet to come. As minimally invasive and economically affordable, serum 
biomarkers for neurodegenerative diseases gained increasing attention in recent years.  
Both preclinical and clinical evidence support the hypothesis that Insulin-like growth factor 1 (IGF-
1) is involved in neuroprotection and plays a role in determining cognitive deficits: a) animal and in 
vitro studies show that IGF-1 is critical for neuronal cell functioning, enhancing neuronal survival 
and inhibiting apoptosis and Β-amyloid deposition [3-5]; b) studies disclose cognitive impairment 
in children with growth hormone (GH) deficit [6]; c) cross-sectional epidemiologic studies report an 
association between low IGF-1 levels and reduced cognitive performance in healthy, elderly 
subjects [7,8], with particular regard to executive function, working memory and attention tasks [9]; 
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d) prospective studies demonstrate that higher serum IGF-1 levels are associated with less cognitive 
decline in the elderly [10-13].  
In keeping with this evidence, we reported a significant association between low serum IGF-1 
levels and poor performances on executive tasks at PD diagnosis and on attention/executive and 
verbal memory tasks after two-years since diagnosis in a cohort of 65 drug-naïve, early patients, 
suggesting a link between IGF-1 and early cognitive impairment in PD [14]. 
In the present study, we sought to analyze the relationship between serum IGF-1 levels and 
cognitive scores at diagnosis in a larger cohort of drug-naïve PD patients. Based on previous 
evidence, lower serum IGF-1 levels were expected to be associated with worse cognitive 
performances. Furthermore, the association between IGF-1 levels and cognition was explored in a 
large cohort of healthy controls (HC).  
Methods 
Data used for this study were obtained from the Parkinson’s Progression Markers Initiative (PPMI) 
database (www.ppmi-info.org/data). PPMI-a public-private partnership-is funded by the Michael J. 
Fox Foundation for Parkinson’s Research and funding partners (www.ppmi-
info.org/fundingpartners). The aims and methodology of the study are available at www.ppmi-
info.org/study-design.  The study was approved by the institutional review board at each site, and 
participants provided written informed consent. For up-to-date information on the study visit 
www.ppmi-info.org. 
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PD patients were enrolled in the PPMI study provided they were drug-naïve, had less than 2-years 
disease duration and evidence of dopamine transporter (DAT) deficit on DAT Scan imaging. 
Enrolled subjects underwent scheduled assessments to collect clinical data and biospecimens every 
3 months for the first year and then every 6 months up to 5 years. Disease severity has been 
assessed by means of the Movement Disorders Society version of the Unified Parkinson’s disease 
rating scale part III (MDS-UPDRS-III). 
Baseline serum samples for the IGF-1 analysis were obtained from the PPMI (Cognition 
biomarkers, 2013; Grant ID 8800; www.ppmi-info.org/access-data-specimens/request-specimens/). 
Demographic, clinical and neuropsychological data were gathered from the PPMI database 
according to guidelines for data access and use (http://www.ppmi-info.org/data).  
According to PPMI Laboratory Manual, venous blood samples from PD patients and HC were 
drawn at baseline visit in the morning after an overnight fast. Blood samples were centrifuged and 
serum was frozen (-80°C). Serum samples from 405 PD patients and 191 HC collected at the 
baseline assessment of the PPMI were shipped on dry ice and analyzed at the Department of 
Clinical Medicine and Surgery, Federico II University, Naples. 
IGF-1 Measurement 
We performed the IGF-1 measurement using the Quantikine Human IGF-1 Immunoassay (R&D 
Systems, Minneapolis, MN, USA), that is a solid-phase ELISA designed to measure human IGF-1 
in serum and plasma. The immunoassay is calibrated against a highly purified Escherichia coli-
expressed recombinant human IGF-1. To reduce analytical variance, samples were batch analyzed 
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using the same assay lot. Serum was pretreated to release IGF-1 from IGF-binding proteins with 
acid-ethanol extraction. Each sample was tested twice in the same assay and the mean of these two 
values was considered for statistical analysis. The NIBSC/WHO IGF-1 International Reference 
Reagent 02/254 was evaluated in this assay. The minimal detectable dose (MDD) of IGF-1 in this 
assay ranged from 0.007 to 0.056 ng/ml and the mean MDD was 0.026 ng/ml. The intra-assay 
coefficients of variation (CVs) were 3.5%, 4.3% and 4.3%, and the inter-assay CVs were 8.1%, 
8.3% and 7.5% for low, medium and high points of the standard curve, respectively. 
Cognitive evaluation 
Global cognition was screened with the Montreal Cognitive Assessment (MoCA) [15]. An 
extensive battery of neuropsychological tests was administered to evaluate different cognitive 
domains. In detail, memory was tested with the Hopkins Verbal Learning Test-Revised (HVLT-R) 
[16]; visuospatial function with the Benton Judgment of Line Orientation (JOLO) 15-item version 
[17]; processing speed-attention with the Symbol-Digit Modalities Test (SDMT) [18]; and 
executive function and working memory with Letter-Number Sequencing (LNS) [19] and semantic 
fluency (SF) [20]. With regard to HVLT-R, Immediate Recall (IR), Delayed Recall (DLRY), 
Retention and Discrimination recognition (DR) were analyzed. Language domain was not assessed. 
Statistical analysis 
Differences in the distribution of categorical variables among groups were assessed by the chi-
square test. After Kolmogorov-Smirnov testing for normal distribution, parametric testing was 
performed for group comparisons (independent sample t-test or one-way ANOVA with post-hoc 
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Bonferroni test, as applicable). Descriptive statistics are given as means and standard deviation 
(SD) with range.  
Those variables of interest assessing specific cognitive domains (ie, all except the MoCA score) 
reaching a significance threshold≤0.1 further underwent linear regression analysis to evaluate the 
association between serum IGF-1 levels and cognitive scores. Based on the observation that only 
the lowest quartile of IGF-1 tended to present worse cognitive outcomes compared to the other 
three quartiles (Figure 1 and Table 1), further analysis were performed comparing the lowest IGF-1 
quartile to all other quartiles combined. Visual inspection of graphs also confirmed the lowest IGF-
1 quartile tended to present worse scores. Linear regression analysis included age, education, 
gender as covariates with no interaction terms. Education years were divided into 2 groups based on 
the median (16 years); group 0: ≤16 years, group 1: >16 years. Results were considered statistically 
significant at p<0.05.  
Results 
Demographic and clinical data of PD patients are reported in Table 1. Serum IGF-1 and age were 
not different between PD and HC (136.6±56.1 vs 134.45±56.13 ng/ml; p=0.64). Serum IGF-1 levels 
were divided in quartiles as follows: lowest quartile ≤ 97.9 ng/ml; second quartile=97.9001-124 
ng/ml; third quartile=124.0001-162.200 ng/ml; highest quartile ≥ 162.2001 ng/ml.  
Linear regression analysis showed that in PD patients the lowest IGF-1 quartile was associated to 
worse performances in several cognitive tasks compared to all the others quartiles (Table 2). In 
detail, the lowest IGF-1 quartile was a predictor of lower scores at the SF task (p=0.005), along 
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with age (p<0.001), male gender (p<0.001) and education (p=0.001) (Figure 1A). Lower 
performances at the SDMT were associated to the lowest IGF-1 quartile (p=0.034), age (p<0.001) 
and male gender (p=0.001) (Figure 1B). Finally, the lowest IGF-1 quartile was a predictor of lower 
performances at the HVLT Retention (p=0.019), along with age (p=0.001) and male gender 
(p=0.003) (Figure 1C).  
No significant associations were found between IGF-1 and any of the neuropsychological tasks in 
HC.  
Discussion 
Confirming our hypothesis, we demonstrated that lower serum IGF-1 levels are associated with 
lower performances on cognitive tasks in a large cohort of early, drug-naïve PD patients. In detail, 
lower serum IGF-1 levels are linked to poor performances in cognitive tasks assessing executive 
function, attention and verbal memory. Deficits in such tasks are driven by a dysfunction in the 
prefrontal and temporal cortex. In detail, neuroimaging studies suggest that while the capability of 
holding information and sustaining attention (evaluated with the retention and delayed recall of 
words list and the SDMT) are both ensured by the prefrontal cortex [21], the ability to access the 
conceptual knowledge stores (evaluated by the Semantic fluency task) is provided by the temporal 
cortex [22]. Therefore, our data suggest that low IGF-1 levels are linked to impaired cognitive 
functions (i.e. cognitive flexibility, attention, devising a search strategy) mediated by prefrontal and 
temporal cortex. 
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In spite of using different neuropsychological tests, these results are consistent with our previous 
study in a cohort of 65 drug-naïve, early PD patients showing a significant correlation between low 
serum IGF-I levels and poor performance on both executive tasks at baseline and  
attention/executive and verbal memory tasks at 2-year follow-up [14]. Therefore, taken together the 
findings from the current and previous study support the link between IGF-1 and cognitive 
impairment in PD patients even in the earliest stages of disease.  
Although explored in a spoonful of studies [14,23], the relation between IGF-1 and cognitive 
performance in PD is not surprising. Indeed, a relevant number of IGF-1 receptors have been 
reported in several brain areas essential for cognitive performance, with highest concentrations in 
the hippocampus and the frontal cortex [3,24,25]. Preclinical evidence also suggest, IGF-1 plays out 
an active defence mechanism against degeneration of the brain [26]. As a matter of fact, executive 
functioning, memory, attention and verbal fluency present specific improvement in GH-deficient 
populations treated with hormone replacement therapy [27].   
Several preclinical and clinical studies highlighted a link between IGF-1 and neurodegeneration and 
demonstrated that it may play an important neuroprotective role by various mechanisms [28]. 
Indeed, animal and in vitro studies showed that IGF-1 enhances neuronal survival and inhibits 
apoptosis. In both Alzheimer’s disease (AD) models and patients, IGF-1 has been suggested to 
increase Β-amyloid clearance and protect neurons against Β-amyloid toxicity [4,5]. Interestingly, a 
recent study including more than three thousands subjects from the Framingham community 
showed that healthy subjects with IGF-1 in the lowest quartile had a 51% greater risk of developing 
AD and, among persons without dementia, higher levels of IGF-1 were associated with greater 
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brain volumes, strongly suggesting that higher levels of IGF-1 may protect against subclinical and 
clinical neurodegeneration [29]. As regards relationship between IGF-1 and α-synuclein pathology, 
IGF-1 can rescue α-synuclein toxicity and suppress α-synuclein aggregation through the activation 
of Akt pathway in cultured cells [30,31].   
Indeed, the pathophysiology of cognitive impairment in PD is complex. It involves multiple 
neurotransmitter systems and diffuse neurodegeneration, and significant gaps still remain in our 
knowledge of cognitively impaired, non-demented PD patients [32,33]. We acknowledge the range 
of neuropsychological findings in patients attributed to different IGF-1 quartiles is remarkable with 
a great overlap. Although our analysis took into account several additional factors possibly 
influencing cognitive performances in PD patients as age, gender and education, still several aspects 
were omitted. However, as there is a dearth of consistent serum biomarkers in PD, our intent was to 
focus on the role of serum IGF-1 as possible marker of cognitive impairment in a large cohort of 
early stage PD. Future studies should clarify the strength of the relationship between IGF-1 and 
cognitive performances when considering other clinical, genetic and neuroimaging markers. 
In contrast with previous findings [34,35], we found IGF-1 levels similar in PD and HC, implying 
this is not a valid biomarker for PD diagnosis. Godau et al first detected higher IGF-1 levels in PD 
compared to healthy subjects and proposed IGF-1 as a marker for PD diagnosis [36,37]. Then, we 
replicated their findings in our small cohort of de novo PD patients [14,38]. On the other hand, 
Numao et al already reported no difference when comparing IGF-1 levels between Japanese PD 
patients and healthy subjects [39]. Indeed, the present study is the largest conducted so far and the 
sample size may in part account for the discrepancy with previous evidence. 
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Several confounding factors may affect IGF-1 levels including body mass index (BMI), diabetes, 
cancer, thyroid dysfunction, inflammatory diseases and medications as corticosteroids [14,35,38].  
We identified such subjects in the PD PPMI cohort (diabetes: 17; cancer: 11; thyroid dysfunction: 
59; on corticosteroids: 4) and repeated all the analysis after their exclusion. However, results were 
largely confirmed. In addition, such subjects did not show different IGF-1 values. Finally, the 
different IGF-1 quartiles did not display significant differences in terms of BMI (Table 1).  
Our study has some limitations. First, our analysis focused only on the baseline assessments of the 
PPMI study and, thus, included patients with relatively preserved cognitive performances. Being the 
cognitive performances of recruited patients relatively stable over the first 2-year follow up, it is 
challenging nowadays to establish the real significance of any biomarker of cognitive impairment. 
However, the PPMI cohort is currently being followed and the next step is to verify if baseline 
biomarkers levels can predict the onset of PD with dementia on the long-term follow up. Second, in 
spite of being the largest existing cohort of de novo PD patients, subjects enrolled in the PPMI 
study may not completely represent the respective counterparts in standard clinical settings. 
Differently from a previous study analyzing preliminary data from the PPMI cohort (63 PD and 39 
HC), no major differences in cognitive performances have been observed between PD and HC 
[40,41]. It should be noted that the PPMI PD cohort comprises predominantly high-educated 
volunteers committed to clinical examinations, neuroimaging and longitudinal follow-ups. As such, 
PD patients are generally more educated and present better cognitive performances as compared to 
previous, smaller cohorts of PD patients. Thus, our results may be not unhesitatingly generalizable 
to all PD patients. On the other hand, PPMI database ensures high data quality collection. Finally, 
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future studies evaluating the impact of a combined set of biomarkers (eg, IGF-1 and ApoE4 carrier 
status) are warranted. 
In conclusion, this is the first large study to indicate a relationship between IGF-1 and specific 
cognitive functions in early PD patients. Long-term follow up of the same cohort will clarify if 
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Table 1. Characterization of the PD cohort according to IGF-1 quartiles 









quartile (109) p 
IGF-1, 
ng/ml 
33.800-412.200 ≤ 97.9 97.9001-124 124.0001-162.200 ≥ 162.2001 NA 
Demographic and motor variables 
Age, years 
























































6.21 (5.81)  
(6, 30) 






20.25 (8.93)  
(4, 51) 
21.03 (9.38)  
(6, 51) 
20.87 (7.42)    
(6, 39) 
18.44 (8.52)  
(6, 45) 










27.02 (2.32)  
(17, 30) 































8.36 (2.52)  
(0, 12) 
7.95 (2.72)  
(0, 12) 















0.86 (0.19)  
(0, 1.22) 




9.65 (2.54)  
(-2, 12) 
9.51 (2.52)  
(-1, 12) 
9.73 (2.52)  
(-1, 12) 
9.89 (2.54)  
(0, 12) 




10.56 (2.66)  
(2-20) 
10.15 (2.92)  
(4, 20) 
10.41 (2.56)  
(2, 16) 
10.68 (2.71)  
(3, 20) 






























Table 1 legend 
Data are in mean (SD) (range), unless otherwise specified. Significance level≤0.1 are shown in 
italics. 
* p=0.005 for the lowest versus the second quartile; p= 0.002 for the lowest versus the fourth 
quartile. 
§ -0.403, p=0.937 for the lowest versus the second quartile; -1.370, p=0.286 for the lowest versus 
the third quartile; -0.256, p=0.989 for the lowest versus the highest quartile. 
^ -0.615, p=0.543 for the lowest versus the second quartile; -0.835, p=0.101 for the lowest versus 
the third quartile; -0.266, p=0.787 for the lowest versus the highest quartile. 
° -0.075, p=0.060 for the lowest versus the second quartile; -0.045, p=0.608 for the lowest versus 
the third quartile; -0.040, p=0.811 for the lowest versus the highest quartile 
$ -2.848, p=0.547 for the lowest versus the second quartile; -3.827, p=0.109 for the lowest versus 
the third quartile; -2.468, p=0.714 for the lowest versus the highest quartile 
& -2.866, p=0.247 for the lowest versus the second quartile; -2.88, p=0.196 for the lowest versus the 
third quartile; -3.560, p=0.042 for the lowest versus the highest quartile 
BMI: Body Mass Index; HVLT DLRY: Hopkins Verbal Learning Test Delayed Recall; HVLT DR: 
Hopkins Verbal Learning Test Discrimination Recognition; HVLT IR: Hopkins Verbal Learning 
Test Immediate Recall; JOLO: Benton Judgment of Line Orientation (15-item version); LNS: Letter 
Number Sequencing; MDS-UPDRS-III: Movement Disorders Society version of the Unified 
Parkinson’s disease rating scale part III; MoCA: Montreal Cognitive Assessment; SDMT: Symbol 


















Table 2 legend 












IGF-1 lowest quartile  -3.46 (-5.87, -1.01) 0.005 
Gender -7.08 (-9.31, -4.84) <0.001 
Age -0.29 (-0.40, -0.18) <0.001 
Education  3.85 (1.61, 6.09) 0.001 
Symbol Digit Modalities Test  
IGF-1 lowest quartile  -2.09 (-4.02, -0.15) 0.034 
Age -0.44 (-0.53,-0.36) <0.001 
Gender -3.03 (-4.81, -1.24) 0.001 
Education  0.92 (-0.87, 2.71) 0.313 
HVLT retention 
IGF-1 lowest quartile  -0.05 (-0.09,-0.009) 0.019 
Age -0.004 (-0.006, -0.001) 0.001 
Gender -0.06 (-0.10, -0.02) 0.003 
Education  0.04 (0.00, 0.08) 0.052 
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Figure 1: Box plots showing differences in cognitive performances in different IGF-1 quartiles 




Figure 1 legend 
Y axis shows cognitive scores adjusted for age, gender and education according to the regression 
analysis. According to one-way ANOVA, the lowest quartile presents worse performances as 
compared to the other quartiles. *: p<0.001. Outliers are showed as circles. 
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Exploring the association between dopaminergic dysfunction and anxiety 
in de novo Parkinson's disease 
Published in Parkinsonism and related disorders 2017; 37:106-110. 
Abstract 
Objectives: To explore the relationships between nigrostriatal dysfunction and neuropsychiatric 
symptoms (including anxiety, depression and apathy) in a large cohort of newly diagnosed, drug-
naïve Parkinson disease (PD) patients compared to a cohort of healthy controls (HC).   
Methods: This is a cross-sectional analysis of the Parkinson's Progression Markers Initiative 
(PPMI) cohort at baseline, including 405 PD patients and 187 HC. Nigrostriatal degeneration was 
evaluated by means of SPECT DAT scan. Relationships between neuropsychiatric symptoms and 
DAT uptakes were analysed by means of stepwise multiple regression analysis.  
Results: In the PD group, lower DAT uptake in the right caudate was associated with higher STAI 
trait subscore (β=-2.939, 95%CI: -4.634 to -1.254, p=0.001). Depression and apathy scores were not 
related with DAT uptakes. No associations were found in the HC group.  
Conclusions: Our cross-sectional analysis of the PPMI data shows that lower caudate DAT uptake 
is associated with higher level of anxiety. The data strengthens the relationship between 






Neuropsychiatric symptoms are frequent complaints in patients with Parkinson disease (PD) with a 
negative impact on quality of life and associated caregiver burden [1]. Anxiety, depression and 
apathy are among the most common non motor symptoms, being present since the earliest stages of 
the disease [1]. Nigrostriatal dopamine depletion in PD contributes directly to motor symptoms, 
however there is increasing evidence that dopaminergic dysfunction spreading to the anteroventral 
part of the striatum has a major role in determining neuropsychiatric disturbance in PD patients, 
especially in the earliest stage of the disease [2-5]. Data from our single-center cohort of patients 
with newly diagnosed PD suggested an inverse correlation between both anxiety and apathy and 
dopamine transporter (DAT) availability in the right caudate [4,5]. However, previous studies have 
found conflicting results [2,3], likely due to the small sample size.  
The aim of the present study is to investigate the relationships between nigrostriatal denervation and 
neuropsychiatric symptoms (including anxiety, depression and apathy) in a large cohort of newly 
diagnosed, drug-naïve PD patients compared to a cohort of healthy controls (HC). According to our 









Study Participants  
The data used in this study was downloaded from the PPMI database, according to guidelines 
(http://www.ppmi-info.org/data, Grant ID 8800). PPMI is an ongoing, international multicenter 
study designed to identify biomarkers of PD progression.  
PD patients were enrolled in the study if they met the following criteria: a) an asymmetric resting 
tremor or asymmetric bradykinesia; or evidence of either bradykinesia or resting tremor and 
rigidity; b) diagnosed within two years; c) a Hoehn and Yahr stage of I or II; d) age 30 years or 
older at diagnosis; e) evidence of dopamine transporter deficit on SPECT DATscan imaging; and f) 
drug-naïve for PD. Demographically comparable healthy subjects were also recruited into the study 
if they had no current or active neurological disorder, no first-degree relative with PD and no 
detectable evidence of dopamine transporter deficit on the SPECT DAT scan imaging. All 
participants underwent a comprehensive clinical, neuropsychiatric, neuropsychological and imaging 
assessment at enrollment. 
The current analysis includes 405 newly diagnosed, drug-naïve PD patients and 187 HC and their 
clinical, neuropsychiatric and SPECT DAT scan imaging data collected at enrollment (either at 
screening or baseline visit). 
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Clinical and neuropsychiatric evaluations 
Clinical examination included the Movement Disorder Society-sponsored revision of the Unified 
Parkinson’s Disease Rating Scale part III (MDS-UPDRS-III) to evaluate motor dysfunction and 
disease severity [6]. 
Severity of anxiety was assessed by means of the State-Trait Anxiety Inventory (STAI) [7], while 
depressive symptoms were evaluated using the 15- item Geriatric Depression Scale (GDS-15) [8], 
with a cut off score of 5 or more indicating clinically significant symptoms [9]. STAI sub-scores 
can differentiate between the temporary condition of state anxiety (i.e., the temporary fear and 
nervousness due to a certain situation) and the more general and long-lasting trait anxiety (i.e., the 
stress, worry and discomfort perceived in typical situations on a daily basis) [9]. Apathy was 
assessed with the single item from the MDS-UPDRS part I (MDS-UPDRS-I) [6]. Any non-zero 
score was considered as an indicator of presence of apathy. 
SPECT studies 
SPECT studies were performed during the screening visit. All subjects received an intravenous 
injection of 185 MBq of [123I]FP-CIT (DAT scan). The acquisition started between 3.30 and 4.30 
h after the radiotracer injection. This time window between 3 and 6 h allows stable measurement of 
specific-to-non-displaceable ratio of [123I]FP-CIT. Specific acquisition parameters were selected 
for each participating center during a preceding technical visit. Images were acquired with a 128 x 
128 matrix in a step and shoot mode. Subsequently, the raw projection data was reconstructed using 
iterative reconstruction algorithm at a central SPECT Core lab in New Haven, Connecticut, USA. 
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Site-specific attenuation correction was applied to the reconstructed data by an automated ellipse 
drawing technique and corrected for attenuation using Chang’s algorithm (l = 0.06/cm). The site-
specific attenuation co-efficient, l, was based on an anthropomorphic distributed source phantom 
acquired during the preceding technical site visit. Hermes (Hermes Medical Solutions, Stockholm, 
Sweden) and Pmod (PMOD Technologies Ltd., Zurich, Switzerland) brain softwares for 
quantification were used. Spatial normalization was performed in Pmod software using a template 
image derived from the Hermes FP-CIT template based on a European multicenter database of 
healthy controls for [123I]FP-CIT SPECT (ENC-DAT). 
Regions of interest (ROI) were then placed on the left and right caudate, the left and right putamen, 
and the occipital cortex (reference tissue). Count densities for each region were extracted and used 
to calculate striatal binding ratios (SBRs) for each of the 4 striatal regions. SBR was calculated as 
(target region/reference region)-1. 
Statistic analysis 
T tests and chi-squared tests were used for comparisons of demographic, clinical, neuropsychiatric 
and imaging variables between PD and HC. Descriptive statistics are given as means and standard 
deviation (SD). Stepwise multiple linear regression analysis evaluating the association between 
DAT scan uptakes  (right and left caudate and putamen uptakes set as independent variables) and 
neuropsychiatric scores (GDS-15 and STAI sub-scores set as dependent variables) was performed 
both in PD and HC.  As for apathy, multiple logistic regression analysis was used since it was 
evaluated with a dichotomous assessment. All the analyses included age, education, gender and 
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disease severity as assessed by the MDS-UPDRS-III as covariates with no interaction terms. 
Results were considered statistically significant at p<0.05 (two-tailed). Analyses were performed 
with the Statistical Package for the Social Sciences (SPSS) statistics (version 19;SPSS, Inc., 
Chicago, IL). 
Standard protocol approvals, registrations, and patient consents 
Each participating PPMI site obtained written informed consent from all participants, and received 
approval from an ethical standards committee on human experimentation. 
Results 
Demographic, clinical, imaging and neuropsychiatric features of PD and HC are displayed in Table 
1.  
In the PD group, lower DAT uptake in the right caudate was associated with higher STAI trait sub-
score (β=-2.939, 95%CI: -4.634 to -1.254, p=0.001) along with younger age (β=-0.187, 95%CI: -
0.282 to -0.092, p<0.001) and female gender (β=-2.139, 95%CI: -4.051 to -0.226, p=0.029) (Figure 
1). STAI state sub-score and 15-GDS showed no relationship with DAT uptakes. Presence of 
apathy was predicted by MDS-UPDRS-III (β=0.047, p=0.001, OR=1.048, 95%CI=1.020 to -1.078) 
and younger age (β=-0.033, p=0.015, OR=0.968, 95%CI=0.943 to -0.994), but not by any DAT 
uptakes. Given the well-known comorbidity between anxiety, depression and apathy [10-12], the 
regression analysis for anxiety was run again controlling also for the presence of apathy and 
severity of depression and the results were largely confirmed (lower right caudate uptake predicted 
higher STAI trait sub-score, β=-1.536, 95%CI: -2.687 to -0.384, p=0.009).  
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When comparing DAT uptakes between PD patients with and without anxiety (according to the 
STAI total score cut off of 39 [9]), anxious patients (88 out of 405) presented a tendency towards 
significance for lower right caudate uptake (1.918 vs 2.01, p=0.1). 
Finally, we did not detect any difference in executive and attentive functions between anxious and 
non-anxious PD patients (data not shown), further supporting the specificity of the relationship 
between anxiety and caudate uptakes. 
No correlation between neuropsychiatric symptoms and DAT uptakes was found in the HC group.  
Discussion 
Confirming previous findings, a recent paper on PPMI data showed that neuropsychiatric symptoms 
are more common in early, drug-naïve PD compared to the general population [9]. Here, we sought 
to detect associations between striatal dopaminergic dysfunction and anxiety, depression and apathy 
in PPMI cohort. After controlling for possible confounding factors, anxiety severity was found to 
relate to lower right caudate uptake in PD. No such correlation was found in the control group. The 
relationship between dopaminergic dysfunction and anxiety disorders in PD is complex and still 
only partially understood. Neuropsychiatric symptoms in PD are not a mere reaction to motor 
symptoms and chronic disability, but are likely due to the combination of psycho-social factors and 
the underlying cortical-limbic-striatal dysfunction [1].  Regarding the association between 
nigrostriatal DAT availability deficits and anxiety symptoms in PD, previous studies have found 
conflicting results. Weintraub et al., by TRODAT-1 imaging, found left anterior putamen DAT 
availability to be negatively correlated with STAI scores [2]. Conversely, Moriyama et al. found an 
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increased DAT density in left striatum and right putamen in PD patients with social anxiety disorder 
[3]. Different methodologies and definition of anxiety may account for such discrepancies. 
Moreover, both studies enrolled smaller cohorts of PD patients with longer disease duration and 
under dopaminergic treatment [2,3]. Indeed, the results of the present study largely confirm our 
previous data on a smaller cohort of early drug-naïve PD patients suggesting that the association 
between anxiety and right caudate may be specific for drug-naïve patients in the earliest stages of 
the disease [5]. This relationship is not surprising and can be explained in light of the crucial non 
motor role played by the caudate in PD [13]. Indeed, this association suggests a more pronounced 
dysruption of dopaminergic-frontal circuits in PD patients with anxiety. According to the 
dopaminergic theory, the neurodegeneration of mesolimbic and mesocortical dopaminergic 
projections observed as a primary neuroanatomical alteration in PD is strongly associated with 
anxiety [13]. Furthermore, the exclusive association between STAI trait sub-score and DAT binding 
suggests that dopaminergic dysfunction is specifically related to anxiety-related personality traits 
rather than the temporary condition of state anxiety. Although the role of other neurotransmitters 
(i.e. serotonin and noradrenalin) cannot be overlooked, the dopaminergic involvement in anxiety of 
PD is supported by clinical evidence, as the common relationship between anxiety and motor 
fluctuations and the occurrence of anxiety symptoms following  the withdrawal of dopaminergic 
medications [14].  
Indeed, anxiety is also recognized as part of the pre-motor symptoms of PD. A recent population-
based cohort study found that the likelihood of developing PD was greater amongst patients with 
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anxiety than patients without anxiety, and the severity of anxiety correlated with the risk of PD 
[15].  
From a practical standpoint, these results may have treatment implications. For instance, dopamine 
agonists, which help compensate for nigrostriatal dopamine deficiencies in PD [14], may be of 
particular use in PD patients with anxiety. Although ad hoc studies are lacking, we previously 
described a reduction in anxiety prevalence in de novo PD patients after the addiction of the 
dopaminergic treatment [16,17]. 
In contrast to previous findings [2,4], we failed to detect any associations between either depression 
or apathy and DAT availability in PD patients enrolled in PPMI.This discrepancy may reflect the 
different methodologies used to evaluate depressive symptoms and apathy. As for depressive 
symptoms, Weintraub et al. [2] used the depression subscale of Profile of Mood States, whereas 
PPMI study used GDS-15, which disclosed only mild depressive symptoms in PD patients, with 
only 13.9% presenting with significant depression [9]. As for apathy, in contrast to our previous 
study on a smaller cohort of early, drug-naïve patients, where we found an association between 
apathy assessed by Apathy Evaluation Scale and right caudate uptake [4], here the occurrence of 
apathy was evaluated by one single item of the MDS-UPDRS-I which is not considered to be an 
adequate screening measure. Thus, we suggest that both the GDS-15 "floor effect" reflecting mild 
depressive symptoms and the lack of specific scales assessing apathy may in part account for the 
lack of associations with DAT availability in the present study. 
Limitations of the study include the cross-sectional design, which precludes firm conclusions of 
causality, lack of adequate screening measures for apathy (e.g., Apathy Evaluation Scale) and 
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assessment of meso-limbic and meso-cortical dopaminergic dysfunction with appropriate imaging 
techniques.  We acknowledge our data describe only in part the complex scenario underlying 
neuropsychiatric disturbances in PD patients. The mild severity of depressive symptoms and the 
low number of subjects defined depressed according to the GDS-15 cut-off may in part account for 
the lack of association between dopaminergic dysfunction and depression in the PD cohort. As 
such, our results on depression and apathy should be interpreted with caution and deserve further 
investigations. Furthermore, the DAT scan was performed during the screening visit while 
behavioral assessments during the baseline visit (within 45 days from the screening). We cannot 
exclude this timeframe has a role in the lack of association with depression and STAI-state anxiety. 
Despite these drawbacks, this is the largest controlled-study to date assessing the relationship 
between dopaminergic dysfunction and anxiety in PD.  
In conclusion, our cross-sectional analysis of the PPMI data shows that high level of anxiety is 
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Table 1. Demographic, clinical, imaging and neuropsychiatric data of PD and HC. 
 
 PD (n=405) HC (n=187) p 
Age, years  61.20 (9.76) 60.24 (11.21) 0.31 
Gender (M/W, %) 264/140 (65.3/34.7) 121/66 (64.7/35.3) 0.41 
Education, years 15.56 (2.98) 16.12 (2.9) 0.032 
MDS-UPDRS-III  20.25 (8.93) NA NA 







1.98 (0.59) 2.95 (0.63) <0.001 
Left Caudate uptake 1.99 (0.59) 3.0 (0.65) <0.001 
Right Putamen 
uptake 
0.84 (0.36) 2.15 (0.58) <0.001 
Left Putamen uptake 0.81 (0.35) 2.14 (0.56) <0.001 
STAI total score 65.35 (18.47)b 57.03 (14.33) <0.001 
STAI state sub-score 32.93 (10.22)b 28.03 (8.14) <0.001 
STAI trait sub-score 32.39 (9.56)b 29.01 (7.5) <0.001 
GDS-15 score 2.29 (2.37)b 1.28 (2.08) <0.001 
GDS-15 cut off (not 
depressed/depressed) 





80/324 (19.8/80.2) 178/9 (95.1/4.9) <0.001 
 
Table 1 Legend 
Data are expressed in mean (standard deviation) unless otherwise specified. Significant differences 
are in italic. 
a Data available for 404 subjects; b Data available for 400 subjects; B: bilateral; GDS-15: 15-item 
Geriatric Depression Scale; HC: healthy controls; L: left; M: men; MDS-UPDRS-I: the Movement 
Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale part I; MDS-
UPDRS-III: Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease 
Rating Scale part III; NA: not applicable; PD: Parkinson disease; R: right; STAI: State-Trait 





Figure 1. Correlation between right caudate uptake and STAI trait sub-score according to the 




Figure 1 legend 
STAI: State-Trait Anxiety Inventory. 
  
! 49!
Exploring the relationship between cognition and dopaminergic 
dysfunction in de novo Parkinson's disease: a longitudinal prospective 
study 
Plos One (under review) 
Abstract 
Objectives: To explore the relationship between nigrostriatal dopamine uptake at diagnosis and 
both baseline and 2-year longitudinal cognitive scores in a large cohort of drug-naïve (at baseline) 
Parkinson’s disease (PD) patients compared to a matched cohort of healthy controls (HC).  
Methods: This is a longitudinal analysis of the Parkinson's Progression Markers Initiative (PPMI) 
cohort, including 423 PD patients and 196 HC at baseline. Nigrostriatal dopaminergic degeneration 
was evaluated at baseline by means of SPECT dopamine transporter (DAT) scan. Relationships 
between specific cognitive tests and DAT uptake were analysed by means of multivariate linear 
regression analysis controlling for age, gender, education and disease severity. 
Results: At baseline, lower left caudate DAT availability was associated with worse performances 
in the processing speed/attention domain (β=1.535, 95%CI: 0.102 to 2.969, p=0.036), while lower 
right putamen uptake presented a trend towards significance for association with lower verbal 
recognition memory scores (β=1.067, 95%CI: -0.022 to 2.157, p=0.055). At 2-year follow up, lower 
left putamen DAT availability at baseline predicted greater decline in tests evaluating immediate 
(β=-1.42, 95%CI: -2.59 to -0.246, p=0.018) and delayed (β=-0.869, 95%CI: -1.53 to -0.210, 
p=0.009) verbal memory, while higher right caudate DAT availability at baseline presented a trend 
for greater improvement in visuo-spatial performances (β=0.326, 95%CI: -0.012 to 0.664, p=0.059). 
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Conclusions: This data strengthens the relationship between dopaminergic dysfunction and 








Cognitive impairment is a frequent complaint in patients with Parkinson’s disease (PD) with a 
negative impact on quality of life and associated caregiver burden. [1-3] Nigrostriatal dopamine 
depletion in PD contributes directly to motor symptoms, however there is increasing evidence that 
dopaminergic dysfunction in the striatum has a major role also in determining cognitive 
dysfunction, especially in the earliest stages of the disease. [4-8] Recent studies focused their 
attention on PD patients with mild cognitive impairment (PD-MCI), suggesting that striatal 
dopamine depletion disrupts the cortico-striatal pathway and, thus, recruitment of cortical regions 
involved in cognitive tasks in this subgroup of patients. [9-11] Our single-centre experience 
suggests a direct relationship between reduced DAT availability in both caudate and putamen and 
impaired cognitive performances in frontal/executive and visuospatial tasks in newly diagnosed PD. 
[9] However, despite the evidence of a close relationship between nigrostriatal dysfunction and 
cognitive impairment in PD, the role of nigrostriatal deafferentation at disease onset in predicting 
subsequent worsening of specific cognitive performances has been poorly investigated. [7] 
In the present study, we sought to explore the relationship between nigrostriatal uptake at diagnosis 
and 1) cognitive scores at diagnosis and 2) change in cognitive scores from diagnosis to 2-year 




Study Participants  
The data used in this study was downloaded from the PPMI database, according to guidelines 
(http://www.ppmi-info.org/data, Grant ID 8800, last download January 4th 2016). PPMI is an 
ongoing, international multicenter study designed to identify biomarkers of PD progression. 
Detailed descriptions of the study have been published elsewhere. [12] 
PD patients were enrolled in the study if they met the following criteria: a) an asymmetric resting 
tremor or asymmetric bradykinesia; or evidence of (either bradykinesia or resting tremor) and 
rigidity; b) diagnosed within two years; c) a Hoehn and Yahr stage of I or II; d) age 30 years or 
older at diagnosis; e) evidence of dopamine transporter deficit on SPECT DATscan imaging; and f) 
drug-naïve for PD; g) diagnosis of dementia based on site investigator’s clinical impression. 
Demographically comparable healthy subjects were also recruited into the study if they had no 
current or active neurological disorder, no first-degree relative with PD and no detectable evidence 
of dopamine transporter deficit on the SPECT DATscan imaging and a Montreal Cognitive 
Assessment (MoCA) battery score>26 [13]. All participants have been performing scheduled 
assessments to collect biospecimens, clinical, neuropsychological and imaging data from 
enrollment and up to 5-year follow up. 
The current analysis includes 423 newly diagnosed, drug-naïve PD patients and 196 HC and their 
SPECT DAT scan imaging data collected at enrollment and clinical and neuropsychological data 
collected at both enrollment and 2-year follow up.  
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SPECT studies 
SPECT studies were performed during the screening visit. All subjects received an intravenous 
injection of 185 MBq of [123I]FP-CIT (DAT scan). The acquisition started between 3.30 and 4.30 
h after the radiotracer injection. This time window between 3 and 6 h allows stable measurement of 
specific-to-non-displaceable ratio of [123I]FP-CIT. [14] Specific acquisition parameters were 
selected for each participating center during a preceding technical visit. Images were acquired with 
a 128 x 128matrix in a step and shoot mode. Subsequently, the raw projection data was 
reconstructed using iterative reconstruction algorithm at a central SPECT Core lab in New Haven, 
Connecticut, USA. Site-specific attenuation correction was applied to the reconstructed data by an 
automated ellipse drawing technique and corrected for attenuation using Chang’s algorithm (l = 
0.06/cm). The site-specific attenuation co-efficient, l, was based on an anthropomorphic distributed 
source phantom acquired during the preceding technical site visit. Hermes (Hermes Medical 
Solutions, Stockholm, Sweden) and Pmod (PMOD Technologies Ltd., Zurich, Switzerland) brain 
softwares for quantification were used. Spatial normalization was performed in Pmod software 
using a template image derived from the Hermes FP-CIT template based on a European multicenter 
database of healthy controls for [123I] FP-CIT SPECT (ENC-DAT). [15] 
Regions of interest (ROI) were then placed on the left and right caudate, the left and right putamen, 
and the occipital cortex (reference tissue). Count densities for each region were extracted and used 
to calculate striatal binding ratios (SBRs) for each of the 4 striatal regions. SBR was calculated as 
(target region/reference region)-1. 
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Clinical and neuropsychological evaluations 
Clinical examination included the Movement Disorder Society-sponsored revision of the Unified 
Parkinson’s Disease Rating Scale part III (MDS-UPDRS-III) to evaluate motor dysfunction and 
disease severity. [16] 
All patients underwent the MoCA [13] to evaluate global cognitive functioning and a 
comprehensive battery of neuropsychological tests to assess the following cognitive functions: (i) 
verbal learning and memory, by means of the Hopkins Verbal Learning Test – Revised (HVLT-R), 
including the Immediate Recall (IR), Delayed Recall (DLRY), Retention, and Discrimination 
Recognition (DR); [17] (ii) executive function and working memory, with the Letter Number 
Sequencing (LNS) [18] and the Semantic Fluency (Animal, Vegetable, Fruit) tests; [19](iii) 
processing speed/attention with the Symbol Digit Modalities test (SDMT); [20] (iv) visuo-spatial 
functions  with the short version of Benton Judgment of Line Orientation (BJLOT) (15-item 
version). [21] 
Statistic analysis 
T tests and Fisher’s exact tests were used for comparisons of baseline demographic, clinical, 
neuropsychological and imaging variables between PD and HC and values with p ≤ 0.05 were 
regarded as stastistically significant. Descriptive statistics are given as means and standard 
deviation (SD). Multivariate linear regression was used to evaluate the association between baseline 
DAT uptakes (right and left caudate and putamen uptakes set as independent variables) and 
cognitive task scores at baseline and their change from baseline to 2-year follow up (dependent 
! 55!
variables). All the models adjusted for age, education, gender and disease severity as assessed by 
the MDS-UPDRS-III. In addition, the 2-year models also adjusted for levodopa equivalent daily 
dose (LEDD). Baseline DAT uptakes were assessed individually and if any were found to be 
significant at the p < 0.2 level they were assessed together in a single backwards regression model 
with a p < 0.1 inclusion level. All β-values and p-values are from the backwards selection models. 
Statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC). Because this 
study was exploratory in nature, analyses were done without correction for multiple comparisons. 
Standard protocol approvals, registrations, and patient consents 
Each participating PPMI site obtained written informed consent from all participants, and received 
approval from an ethical standards committee on human experimentation. 
Results 
Baseline and 2-year follow up demographic, clinical, imaging and neuropsychological features of 
PD and HC are displayed in Table 1. 
Relationship between DAT uptakes and baseline cognitive performances 
In the PD group, lower left caudate uptake was associated with lower SDMT scores (β=1.535, 
95%CI: 0.102 to 2.969, p=0.036) (Figure 1A), while lower right putamen uptake presented a trend 
towards significance for association with lower HVLT-DR score (β=1.067, 95%CI: -0.022 to 2.157, 
p=0.055) (Figure 1B). In the HC group, lower uptake in the right putamen was found to be 
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associated with reduced MoCA performances (β=0.309, 95%CI: 0.015 to 0.603, p=0.040). No other 
significant associations were detected. 
Relationship between DAT uptakes and change in cognitive performances from baseline to 2-
year follow up 
In the PD group, lower left putamen uptake was associated with greater worsening in HVLT IR 
(β=-1.42, 95%CI: -2.59 to -0.246, p=0.018), HVLT DRLY (β=-0.869, 95%CI: -1.53 to -0.210, 
p=0.009) and HVLT retention (β=-0.069, 95%CI: -0.135 to -0.005, p=0.035). There was a trend 
towards significance for higher right caudate uptake and greater improvement in BJLOT (β=0.326, 
95%CI: -0.012 to 0.664, p=0.059). No significant associations were detected in HC group. 
Discussion 
Regarding baseline analysis, and after controlling for possible confounding factors, we found a 
significant association between left caudate uptake and information processing speed and between 
right putamen uptake and memory task. Although with a different methodology, other analyses of 
the PPMI data already disclosed a relationship between striatal uptake and cognitive performances 
suggesting a role for DAT Scan as an imaging biomarker for cognitive impairment in PD. [6,7,22] 
The present study, however, discloses for the first time the relationship between striatal uptakes and 
specific cognitive functions. Indeed, the association between executive function and caudate DAT 
uptake is well established in early untreated PD and relates to a disruption of the dopaminergic-
frontal circuits. [4,5]  
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Conversely, the association between striatal dopaminergic depletion and memory has only recently 
gained attention. By studying patients with a mean disease duration of 6 years on dopaminergic 
treatment, Christopher et al. suggested that memory impairment in PD is associated with a loss of 
dopaminergic function in the salience network and right para-hippocampal gyrus. [23] They found 
significant differences in [11C] DTBZ binding in associative striatum according to cognitive status, 
with the greatest impairment in PD amnestic MCI. [23] The authors hypothesized that a disruption 
of dopaminergic modulation in the salience network could impact the switch between the central 
executive and default mode network required for mental flexibility and the coordination of memory, 
thus explaining poor executive and memory performances in PD. [23] Our data strongly support the 
role of the striatum in both executive and memory tasks in PD since the early stages of disease. 
Alternatively or complementarily, our findings may also support the hypothesis that PD memory 
impairment is secondary to impaired attention and executive dysfunction. [24] As the cornerstone 
of memory deficit in PD is the retrieval, [23] the lack of association between DAT uptakes and 
HVLT DRLY at baseline would support the latter hypothesis. 
Regarding the role of the dopaminergic dysfunction in predicting cognitive changes at 2-year follow 
up, we found an association between lower left putamen uptake at baseline and greater decline in 
both immediate and delayed recall of the HVLT. This finding is consistent with a recent analysis of 
the PPMI data showing that baseline age, olfaction and REM-sleep behavior disorders scores, 
CSFAΒ42 and DAT uptakes allowed the best prediction of 2-year cognitive impairment as assessed 
with the MoCA scores. [6] The present study, however, analyzes for the first time the relationship 
between baseline DAT uptakes and specific cognitive performances after 2-year follow up. Indeed, 
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a link between memory and activity in both the hippocampus and the putamen during encoding has 
been already shown by fMRI studies in healthy subjects. [25,26] In addition, the association 
between higher right caudate uptake and greater improvement in visuospatial task indicates a role 
for caudate nucleus in visuospatial abilities, as already reported in patients with dementia with 
Lewy bodies. [27] Again, these findings support the central role of frontal circuits in cognitive 
performances in early PD. As a matter of fact, visuospatial abilities in early PD are mainly driven 
by frontal circuits, which have wide connections with posterior visuo-spatial areas, rather than by 
primary posterior cortex. [11]  
Finally, our analysis shows a positive association between MoCA scores and right putamen uptake 
in healthy controls. The MoCA is a screening test assessing multiple functions related to both 
cortical and subcortical areas and widely used in studies involving both subjects affected by 
diseases other than PD and healthy elderly. A recent study shows that MoCA total score is related 
with MRI measures evaluating subcortical atrophy in healthy subjects [28]. Thus, we can argue that 
dopaminergic circuitries have a role in determining MoCA performances in healthy subjects. 
However, the detailed examination of this relationship is outside the scope of the present study. 
Indeed, in spite of being one of the largest existing cohort of de novo PD patients so far, both PD 
and HC subjects enrolled in the PPMI study may not completely represent their respective 
counterparts in standard clinical settings. In fact, although PD patients enrolled in PPMI showed 
lower cognitive performances when compared to healthy controls, [29] they were generally more 
educated and presented better cognitive performances as compared to previous, smaller cohorts of 
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PD patients. [30,31] Thus, our results may not be applied universally to PD patients and healthy 
subjects.  
We acknowledge our data describe only in part the complex scenario underlying cognitive deficits 
in PD patients. Our study misses to consider the role of other neurotrasmitters (e.g., acetylcholine) 
and the dysfunction of other neural networks (e.g., meso-limbic and meso-cortical dopaminergic 
dysfunction detectable with other imaging techniques), which are pivotal in the pathogenesis of 
cognitive impairment in PD. However, the present study was specifically focused on the 
relationship between DAT availability at diagnosis and cognition at baseline and its change after 2-
year follow up, and we believe that the large cohort of PD patients and healthy controls involved in 
this analysis strengthens our results.  
In conclusion, our longitudinal analysis of the PPMI data shows that: a) at diagnosis reduced 
processing speed is related to lower DAT availability in the left caudate and poorer memory scores 
present a trend towards significance for reduced right putamen uptake; b) lower left putamen uptake 
at diagnosis envisages greater decline in working memory after 2-year follow up; and c) higher 
right caudate uptake at diagnosis is associated with better visuo-spatial functions at 2-year follow 
up. This data strengthens the relationship between dopaminergic dysfunction and cognitive 
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Table 1. Demographic, clinical and cognitive data of PD and HC at baseline and 2-year follow 
up. 
 PD (n=423) HC (n=196) p 
Baseline 
Age, years 61.65 (9.7) 60.80 (11.2) 0.33 
Gender (M/W, %) 277/146 (65.4/34.5) 126/70 (64.2/35.7) 0.78 
Education, years 15.54 (2.99) 16.04 (2.89) 0.05 





Right Caudate DAT 
uptakea 
1.99 (0.59) 2.96 (0.63) <0.001 
Left Caudate DAT 
uptakea 
2.00 (0.60) 3.0 (0.65) <0.001 
Right Putamen DAT 
uptakea 
0.84 (0.36) 2.15 (0.58) <0.001 
Left Putamen DAT 
uptakea 
0.81 (0.36) 2.14 (0.57) <0.001 
MDS-UPDRS-III 20.89 (8.86) 1.20 (2.19) <0.001 
MoCAb 27.13 (2.32) 28.23 (1.11) <0.001 
BJLOTc 12.77 (2.13)  13.12 (1.98) 0.051 
HVLT-IRc 24.44 (4.98) 26.05 (4.50) <0.001 
HVLT-DRLYc 8.36 (2.52) 9.29 (2.32) <0.001 
HVLT retentionc 0.86 (0.20) 0.90 (0.18) 0.003 
HVLT DRc 9.63 (2.63) 10.07 (2.80) 0.062 
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LNSc 10.59 (2.66) 10.87 (2.57) 0.21 
Semantic fluencyc 48.67 (11.6) 51.80 (11.2) 0.001 
SDMTc 41.18 (9.73) 46.78 (10.5) <0.001 
2-year follow up 
 PD (n=380) HC (n=174) p 
MDS-UPDRS-III 27.3 (11.3) 1.5 (2.82) <0.001 
MoCA, total score 26.3 (3.16) 27.2 (2.34) <0.001 
BJLOT 12.8  (2.26) 13.1 (2.08) 0.24 
HVLT IR 23.7 (5.45) 25.9 (5.05) <0.001 
HVLT DRLY 8.2 (2.95) 9.2 (2.53) <0.001 
HVLT retention 0.9 (0.23) 0.9 (0.19) 0.03 
HVLT DR 10.7 (2.41) 10.6 (3.0) 0.72 
LNS 10.3 (2.81) 10.9 (2.51) 0.01 
Semantic fluency 49 (13) 56.2 (11.7) 0.002 
SDMT 40 (11.1) 46.5 (10.7) <0.001 
 
Table 1 legend 
Data is in mean (standard deviation) unless otherwise specified. Significant differences are in italic. 
a Data available for 418 PD and 193 HC; b Data available for 420 PD and  196 HC; c Data available 
for 422 PD and 196 HC; B: bilateral; BJLOT: Benton Judgment of Line Orientation test; HC: 
healthy controls; HVLT-DLRY: Hopkins Verbal Learning Test Delayed Recall; HVLT-DR: 
Hopkins Verbal Learning Test discrimination recognition; HVLT-IR: Hopkins Verbal Learning 
Test immediate recall; L: left; LNS: Letter Number Sequencing; M: men; MDS-UPDRS-I: the 
Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale 
part I; MDS-UPDRS-III: Movement Disorder Society-sponsored revision of the Unified 
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Parkinson’s Disease Rating Scale part III; MoCA: Montreal Cognitive Assessment; NA: not 




Figure 1: A) Correlation between left caudate uptake and SDMT according to the multiple 
linear regression model; B) Correlation between right putamen uptake and HVLT-DR 




Figure 1 legend 
Y axis shows standardized scores. Abbreviations: HVLT DR: Hopkins Verbal Learning Test 
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